Combining Christian's and Reinhold's expertise in academia with Jens's career in the industry, cpo translates this knowledge to contribute to the fight against cancer by developing innovative patient-derived cell culture models.   

OUR NAME

cellular means related to the cell (from Latin cella, "small room"). The cell is the basic structural, functional and biological unit of all known living organisms. Cells are the smallest unit of life that can replicate independently, and are often called the building blocks of life. 

phenomics measures and describes phenomes — the physical and biochemical traits of living systems (may it be a single cell or a whole organism) as they change in response to genetic mutation and environmental influences. We at cpo use the term to sum total the interactions between functional genomics, pharmaceutical research and metabolic response as we try translating both qualitatively and quantitatively measurements of phenomes into better treatments for cancer patients.

oncology is a branch of medicine that deals with tumors. Neoplasms (from Ancient Greek neo "new" and plasma "formation") as tumors are also commonly referred to are an abnormal growth of tissue. A malignant neoplasm is a cancer.

OUR MISSION

cpo is a state-of-the-art in vitro service provider aimed at offering high-quality, reasonable priced cell culture models complementing classical in vivo assays using patient-derived 3D cell cultures. We view ourselves as partners with our customers, our employees, our scientific community and our environment. Our mission is to help the biotech and pharma industries create innovative testings of novel anti-cancer drugs. We are committed to help oncologists and their patients make informed choices to improve quality of lives. We aim to become a recognized brand name in the field of preclinical testing, capitalizing on the sustained interest in alternatives to animal testing. Our goal is satisfied customers, moderate growth, annual profitability and maintaining our sense of humor.

FOUNDERS

Dr. Christian Regenbrecht

founder & ceo

MAIL TO

Christian has studied biology and philosophy at the University of Bonn. In 2005 he did his first postdoc with Hans Lehrach at the Max Planck Institute for Molecular Genomics in Berlin. In 2010 his group moved to the Institute for Pathology at the Charité - Universitätsmedizin Berlin focussing on improved patient-derived in vitro models. During his time at the Charité he was appointed head of the core-facility for functional genomics of the Charité. Within the IMI initiative Oncotrack Christian was the the academic lead of the work package in vitro models & cancer stem cells.

In 2012 he, together with SAP was awarded with the Innovation award of the states Berlin and Brandenburg for his work on the Oncolyzer, a mobile-device app that allows to analyze clinical records of cancer-patients in real-time.

Since May 2017 he is speaker and member of the advisory committee for Berlin's "Pharma Solutions" ZIM cluster.

Christian is member of distinguished national and international scientific societies, including the New York Academy of Sciences (NYAS), the American Association for Cancer Research (AACR), the European Association for Cancer Research (EACR), the Connective Tissue Oncology Society (ctos),the German Cancer Society (DKG) and Berlin's Cancer Society (BKG).

Joseph L Regan, Dirk Schumacher, Stephanie Staudte, Andreas Steffen, Johannes
Haybaeck, Ulrich Keilholz, Caroline Schweiger, Nicole Golob-Schwarzl, Dominik Mumberg, David Henderson, Hans Lehrach, Christian RA Regenbrecht, Reinhold Schäfer, Martin Lange: Non-Canonical Hedgehog signaling is a positive regulator of the WNT pathway and is required for the survival of colon cancer stem cells. Cell Reports (accepted)

Manuela Gaebler, Alessandra Silvestri, Johannes Haybaeck, Peter Reichardt, Caitlin D. Lowery, Louis F. Stancato, Gabriele Zybarth and Christian R. A. Regenbrecht. Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management. Front Onc. 2017 Sep 11

Nicole Golob-Schwarzl, Caroline Schweiger, Carina Koller,[…], Christian RA Regenbrecht, […], Johannes Haybaeck. Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6. Oncotarget. 2017 Sep.

Schütte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D […], Regenbrecht CRA et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun. 2017 Feb 10;8:14262. PubMed PMID: 28186126.

Redmer T, Walz I, Klinger B, Khouja S, Welte Y, Schäfer R, Regenbrecht C. The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. Oncogenesis. 2017 Jan 23;6(1):e291. doi: 10.1038/oncsis.2016.88. PMID: 28112719

Boehnke K, Iversen PW, Schumacher D, Lallena MJ, Haro R, Amat J, Haybaeck J, Liebs S, Lange M, Schäfer R, Regenbrecht CR, Reinhard C, Velasco JA. Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures. Journal of biomolecular screening. 2016; 21(9):931-41. PubMed [journal] PMID: 27233291, PMCID: PMC5030729

Wruck W, Kashofer K, Rehman S, Daskalaki A, Berg D, Gralka E, Jozefczuk J, Drews K, Pandey V, Regenbrecht C RA, Wierling C, Turano P, Korf U, Zatloukal K, Lehrach H, Westerhoff HV, Adjaye J. Multi-omic profiles of human non-alcoholic fatty liver disease tissue highlight heterogenic phenotypes. Sci Data. 2015 Dec 8;2:150068. doi: 10.1038/sdata.2015.68. PubMed PMID: 26646939; PubMed Central PMCID: PMC4672680.

Soysal SD, Kilic IB, Regenbrecht C RA, Schneider S, Muenst S, Kilic N, Güth U, Dietel M, Terracciano LM, Kilic E. Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer. Breast Cancer Res Treat. 2015 Jun;151(3):709-15. doi: 10.1007/s10549-015-3427-y. Epub 2015 May 16. PubMed PMID: 25981900.

Redmer T, Welte Y, Behrens D, Fichtner I, Przybilla D, Wruck W, Yaspo ML, Lehrach H, Schäfer R, Regenbrecht CR. The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells. PloS one. 2014; 9(5):e92596. PubMed [journal] PMID: 24799129, PMCID: PMC4010406

Henderson D, Ogilvie LA, Hoyle N, Keilholz U, Lange B, Lehrach [...] Regenbrecht C RA. Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. Biotechnol J. 2014 Sep;9(9):1104-14. doi:10.1002/biot.201400109. Epub 2014 Jul 29. PubMed PMID: 25074435.

Banning A, Regenbrecht C RA, Tikkanen R. Increased activity of mitogen activatedprotein kinase pathway in flotillin-2 knockout mouse model. Cell Signal. 2014 Feb;26(2):198-207. doi: 10.1016/j.cellsig.2013.11.001. Epub 2013 Nov 9. PubMedPMID: 24216609.

Wruck W, Peuker M, Regenbrecht CR. Data management strategies formultinational large-scale systems biology projects. Brief Bioinform. 2014 Jan;15(1):65-78. doi: 10.1093/bib/bbs064. Epub 2012 Oct 9. Review. PubMed PMID:23047157; PubMed Central PMCID: PMC3896927.

Redmer T, Welte Y, Behrens D, Fichtner I, Przybilla D, Wruck W, Yaspo ML,Lehrach H, Schäfer R, Regenbrecht C RA. The nerve growth factor receptor CD271 iscrucial to maintain tumorigenicity and stem-like properties of melanoma cells.PLoS One. 2014 May 5;9(5):e92596. doi: 10.1371/journal.pone.0092596. eCollection 2014. PubMed PMID: 24799129; PubMed Central PMCID: PMC4010406.

Busse A, Letsch A, Fusi A, Nonnenmacher A, Stather D, Ochsenreither S, Regenbrecht C RA, Keilholz U. Characterization of small spheres derived fromvarious solid tumor cell lines: are they suitable targets for T cells? Clin ExpMetastasis. 2013 Aug;30(6):781-91. doi: 10.1007/s10585-013-9578-5. Epub 2013 Mar 22. PubMed PMID: 23519726.

Welte Y, Davies C, Schäfer R, Regenbrecht CR. Patient derived cell culture andisolation of CD133⁺ putative cancer stem cells from melanoma. J Vis Exp. 2013 Mar13;(73):e50200. doi: 10.3791/50200. PubMed PMID: 23525090.

Jozefczuk J, Kashofer K, Ummanni R, Henjes F, Rehman S, Geenen S, Wruck W, Regenbrecht C, Daskalaki A, Wierling C, Turano P, Bertini I, Korf U, Zatloukal K,Westerhoff HV, Lehrach H, Adjaye J. A Systems Biology Approach to Deciphering theEtiology of Steatosis Employing Patient-Derived Dermal Fibroblasts and iPS Cells.Front Physiol. 2012 Sep 3;3:339. doi: 10.3389/fphys.2012.00339. eCollection 2012.PubMed PMID: 22969728; PubMed Central PMCID: PMC3432516.

Duenisch P, Reichart R, Mueller U, Brodhun M, Bjerkvig R, Romeike B, Walter J, Herbold C, Regenbrecht CR, Kalff R, Kuhn SA. Neural cell adhesion moleculeisoform 140 declines with rise of WHO grade in human gliomas and serves asindicator for the invasion zone of multiform glioblastomas and brain metastases. J Cancer Res Clin Oncol. 2011 Mar;137(3):399-414. doi: 10.1007/s00432-010-0888-6.Epub 2010 May 4. PubMed PMID: 20440511.

Welte Y, Adjaye J, Lehrach HR, Regenbrecht CR. Cancer stem cells in solidtumors: elusive or illusive? Cell Commun Signal. 2010 May 11;8(1):6. doi:10.1186/1478-811X-8-6. PubMed PMID: 20459772; PubMed Central PMCID: PMC2880310.

Brink TC, Regenbrecht C, Demetrius L, Lehrach H, Adjaye J. Activation of theimmune response is a key feature of aging in mice. Biogerontology. 2009Dec;10(6):721-34. doi: 10.1007/s10522-009-9219-1. PubMed PMID: 19255868; PubMedCentral PMCID: PMC2778679.

Kuhn SA, Mueller U, Hanisch UK, Regenbrecht CR, Schoenwald I, Brodhun M,Kosmehl H, Ewald C, Kalff R, Reichart R. Glioblastoma cells express functionalcell membrane receptors activated by daily used medical drugs. J Cancer Res Clin Oncol. 2009 Dec;135(12):1729-45. doi: 10.1007/s00432-009-0620-6. Epub 2009 Jun19. PubMed PMID: 19543745; PubMed Central PMCID: PMC2847174.

Frank S, Kuhn SA, Brodhun M, Mueller U, Romeike B, Kosmehl H, Regenbrecht CR, Ewald C, Reichart R, Kalff R. Metastatic glioblastoma cells use common pathwaysvia blood and lymphatic vessels. Neurol Neurochir Pol. 2009 Mar-Apr;43(2):183-90.PubMed PMID: 19484696.

Regenbrecht CR, Lehrach H, Adjaye J. Stemming cancer: functional genomics of cancer stem cells in solid tumors. Stem Cell Rev. 2008 Dec;4(4):319-28. doi:10.1007/s12015-008-9034-0. Review. PubMed PMID: 18561035; PubMed Central PMCID:PMC2758383.

Regenbrecht CR, Jung M, Lehrach H, Adjaye J. The molecular basis ofgenistein-induced mitotic arrest and exit of self-renewal in embryonal carcinoma and primary cancer cell lines. BMC Med Genomics. 2008 Oct 10;1:49. doi:10.1186/1755-8794-1-49. PubMed PMID: 18847459; PubMed Central PMCID: PMC2577110.

 

Dr. Jens Hoffmann

founder

 MAIL TO

Jens has studied pharmaceutics at Ernst-Moritz-Arndt-University which he successfully finished in 1989. He than started working as a staff scientist at the central institute for cancer research at the highly renowed Academy of Sciences in Berlin-Buch in the department for clinical pharmacology. Before his PhD thesis, he was visiting scientist at the German Cancer Research Institute (DKFZ) in Heidelberg. In 1995 Jens received his PhD from Berlin’s Humboldt University and moved on to Bayer-Schering, where he received a stipend as a visiting scientist at the department of pharmacology at University of Pittsburg. Until 2009 he was Group leader at Bayer Pharma AG in Berlin. Since 2010 Jens is CEO of EPO - experimental pharmacology & oncology Berlin-Buch GmbH.

Jens is visiting scientist at the Max-Delbrück Center (MDC) and at the Charité Comprehensive Center (CCCC). He has a teaching assignment at Freie Universität (FU) Berlin.

Schmieder R, Hoffmann J, Becker M, Bhargava A, Müller T, Kahmann N, Ellinghaus P, Adams R, Rosenthal A, Thierauch KH, Scholz A, Wilhelm SM, Zopf D. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer. 2014 Sep 15;135(6):1487-96. doi: 10.1002/ijc.28669. Epub 2014 Apr 17. PubMed PMID: 24347491.

Busia L, Faus H, Hoffmann J, Haendler B. The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression. Mol Cell Endocrinol. 2011 Feb 10;333(1):37-46. doi: 10.1016/j.mce.2010.11.034. Epub 2010 Dec 5. PubMed PMID: 21138753.

Eschenbrenner J, Winsel S, Hammer S, Sommer A, Mittelstaedt K, Drosch M, Klar  U, Sachse C, Hannus M, Seidel M, Weiss B, Merz C, Siemeister G, Hoffmann J. Evaluation of activity and combination strategies with the microtubule-targeting  drug sagopilone in breast cancer cell lines. Front Oncol. 2011 Nov 16;1:44. doi:  10.3389/fonc.2011.00044. eCollection 2011. PubMed PMID: 22649765; PubMed Central  PMCID: PMC3355879.

Hammer S, Sommer A, Fichtner I, Becker M, Rolff J, Merk J, Klar U, Hoffmann J. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived  from primary non-small cell lung cancer. Clin Cancer Res. 2010 Mar 1;16(5):1452-65. doi: 10.1158/1078-0432.CCR-09-2455. Epub 2010 Feb 23. PubMed PMID: 20179216.

Afhüppe W, Beekman JM, Otto C, Korr D, Hoffmann J, Fuhrmann U, Möller C. In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties. J Steroid Biochem Mol Biol. 2010 Mar;119(1-2):45-55. doi: 10.1016/j.jsbmb.2009.12.011. Epub 2010 Jan 4. PubMed PMID: 20043998.

Strube A, Hoffmann J, Stepina E, Hauff P, Klar U, Käkönen SM. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption. Clin Cancer Res. 2009 Jun 1;15(11):3751-9. doi: 10.1158/1078-0432.CCR-08-3123. Epub 2009 May 26. PubMed PMID: 19470728.

Hoffmann J, Fichtner I, Lemm M, Lienau P, Hess-Stumpp H, Rotgeri A, Hofmann B, Klar U. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol. 2009 Apr;11(2):158-66. doi: 10.1215/15228517-2008-072. Epub 2008 Sep 9. PubMed PMID: 18780814; PubMed Central PMCID: PMC2718987.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138. PubMed PMID: 18927285.

Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, Panaretakis T, Siemeister G, Lage H, Nanty  L, Hammer S, Mittelstaedt K, Winsel S, Eschenbrenner J, Castedo M, Demarche C, Klar U, Kroemer G. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res. 2008 Jul 1;68(13):5301-8. doi: 10.1158/0008-5472.CAN-08-0237. PubMed PMID: 18593931.

Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl. 2006 Dec 4;45(47):7942-8. PubMed PMID: 17006870.

Zajchowski DA, Biroc SL, Liu HL, Chesney SK, Hoffmann J, Bauman J, Kirkland T, Subramanyam B, Shen J, Ho E, Tseng JL, Dinter H. Anti-tumor efficacy of the nucleoside analog 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl) cytosine (4'-thio-FAC) in human pancreatic and ovarian tumor xenograft models. Int J Cancer. 2005 May 10;114(6):1002-9. PubMed PMID: 15645422.

Hoffmann J, Sommer A. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches. J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):191-200. Epub 2005 Jan 28. PubMed PMID: 15860262.

Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Künzer H, Lichtner RB, Nishino Y, Parczyk K, Sauer G, Gieschen H, Ulbrich HF, Schneider MR. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer. J Natl Cancer Inst. 2004 Feb 4;96(3):210-8. PubMed PMID: 14759988.

Sommer A, Hoffmann J, Lichtner RB, Schneider MR, Parczyk K. Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines. J Steroid Biochem Mol Biol. 2003 May;85(1):33-47. PubMed PMID: 12798355.

Eder IE, Hoffmann J, Rogatsch H, Schäfer G, Zopf D, Bartsch G, Klocker H. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther. 2002 Feb;9(2):117-25. Erratum in: Cancer Gene Ther. 2007 Nov;14(11):934. PubMed PMID: 11857028.

Fuhrmann U, Hess-Stumpp H, Cleve A, Neef G, Schwede W, Hoffmann J, Fritzemeier KH, Chwalisz K. Synthesis and biological activity of a novel, highly  potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6. PubMed PMID: 11150172.

Hoffmann J, Schmidt-Peter P, Hänsch W, Naundorf H, Bunge A, Becker M, Fichtner I. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas. Clin Cancer Res. 1999 Aug;5(8):2198-204. PubMed PMID: 10473106.

Schirner M, Hoffmann J, Menrad A, Schneider MR. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res. 1998 May;4(5):1331-6. PubMed PMID: 9607594.

Hoffmann J, Schirner M, Menrad A, Schneider MR. A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res. 1997 Sep 1;57(17):3847-51. PubMed PMID: 9288798.

Hoffmann J, Fichtner I, Becker M, Lemm M. [Measurement of bromsulfalein retention in the mouse as a possible parameter for assessment of liver function after administration of liposomal preparations]. Pharmazie. 1991 Mar;46(3):222-3. German. PubMed PMID: 1881948.

Prof. Dr. Reinhold Schäfer

founder

MAIL TO

Reinhold studied biology at Rheinische Friedrich-Wilhelms-University in Bonn. He received a PhD in biology in 1976. He did postdoctoral work at the Max-Planck-Institute of Experimental Medicine in Göttingen and at the Institute of Cell Biology (Tumor Research), the West German Cancer Center, University Hospital Essen. He became staff scientist and group leader at the Ludwig Institute for Cancer Research in Berne, Switzerland, in 1985 and was appointed head of the Division of Cancer Research, Department of Pathology, University of Zürich in 1988. He worked as Professor of Molecular Tumor Pathology at Charité Universitätsmedizin Berlin from 1996-2016. He coordinated the Berlin site within the German Cancer Consortium (DKTK) from 2012-2016. Currently, he is deputy director of the Charité Comprehensive Cancer Center and is working as researcher and advisor within the DKTK and fellow at the German Cancer Research Center (DKFZ) in Heidelberg.

Schütte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M, Yildiriman R, Jandrasits C, Borodina T, Amstislavskiy V, Worth CL, Schweiger C, Liebs S, Lange M, Warnatz HJ, Butcher LM, Barrett JE, Sultan M, Wierling C, Golob-Schwarzl N, Lax S, Uranitsch S, Becker M, Welte Y, Regan JL, Silvestrov M, Kehler I, Fusi A, Kessler T, Herwig R, Landegren U, Wienke D, Nilsson M, Velasco JA, Garin-Chesa P, Reinhard C, Beck S, Schäfer R, Regenbrecht CR, Henderson D, Lange B, Haybaeck J, Keilholz U, Hoffmann J, Lehrach H, Yaspo ML. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun. 8:14262. doi: 10.1038/ncomms14262

Mamlouk S, Childs LH, Aust D, Heim D, Melching F, Oliveira C, Wolf T, Durek P, Schumacher D, Bläker H, von Winterfeld M, Gastl B, Möhr K, Menne A, Zeugner S, Redmer T, Lenze D, Tierling S, Möbs M, Weichert W, Folprecht G, Blanc E, Beule D, Schäfer R, Morkel M, Klauschen F, Leser U, Sers C. DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. Nat Commun. 8: 14093. doi: 10.1038/ncomms14093

Redmer T, Walz I, Klinger B, Khouja S, Welte Y, Schäfer R, Regenbrecht C. The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. Oncogenesis. 23;6(1):e291. doi: 10.1038/oncsis.2016.88.

Boehnke K, Iversen PW, Schumacher D, Lallena MJ, Haro R, Amat J, Haybaeck J, Liebs S, Lange M, Schäfer R, Regenbrecht CR, Reinhard C, Velasco JA. Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures. J Biomol Screen. 21(9):931-41. doi: 10.1177/1087057116650965.

Rohr I, Braicu E, En-Nia A, Heinrich M, Richter R, Chekerov R, Dechend R, Heidecke H, Dragun D, Schäfer R, Gorny X, Lindquist JA, Brandt S, Sehouli J, Mertens PR. Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC). Cytokine. 85:157-64. doi: 10.1016/j.cyto.2016.06.021. 

Roßner F, Gieseler C, Morkel M, Royer H-D, Rivera M, Bläker H, Dietel M, Schäfer R, and Sers C. Uncoupling of EGFR-RAS signaling and nuclear localization of YBX1 in colorectal cancer. Oncogenesis, accepted

Győrffy B, Stelniec-Klotz I, Sigler C, Kasack K, Redmer T, Qian, Y and Schäfer R. Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer. Oncotarget, 30;6(15):13334-46.

Relógio A, Thomas P, Medina-Pérez P, Reischl S, Bervoets S, Gloc E, Riemer P, Mang-Fatehi S, Maier B, Schäfer R, Leser U, Herzel H, Kramer A, Sers C. Ras-mediated deregulation of the circadian clock in cancer. PLoS Genet. 29;10(5):e1004338. 

Riemer P, Sreekumar A, Reinke S, Rad R, Schäfer R, Sers C, Bläker H, Herrmann BG, Morkel M. Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity. Oncogene, 34(24):3164-75

Redmer T, Welte Y, Behrens D, Fichtner I, Przybilla D, Yaspo ML, Lehrach H, Schäfer R and Regenbrecht CRA. The Nerve Growth Factor Receptor CD271 is Crucial to Maintain Tumorigenicity and Stem-Like Properties of Melanoma Cells.  PLoS One 9(5): e92596.

Klinger B, Sieber A, Fritsche-Guenther R, Witzel F, Berry L, Schumacher D, Yan Y, Durek P, Merchant M, Schäfer R, Sers C, Blüthgen N. Network quantification of EGFR signaling unveils potential for targeted combination therapy. Mol Syst Biol. 9:673. 

Penzvaltó Z, Tegze B, Szász AM. Sztupinszki Z, 1, Likó I, Szendröi A, Schäfer R, and Györffy B. Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines. PLoS One 8, e59503.

Malek A, Györffy B, Catapano CV and Schäfer R. Selection of optimal combinations of target genes for therapeutic multi-gene silencing based on miRNA co-regulation. Cancer Gene Therapy 20(5):326-9

Welte Y, Davies C, Schäfer R, Regenbrecht CRA. Patient derived cell culture and isolation of CD133+ putative cancer stem cells from melanoma. J. Vis. Exp. e50200, doi:10.3791/50200.

Stelniec-Klotz I, Legewie S, Tchernitsa O, Witzel F, Klinger B, Sers C, Herzel H, Bluthgen N, Schäfer R. Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS. Mol Syst Biol 8:601. 

Gyorffy B, Benke Z, Lanczky A, Balazs B, Szallasi Z, Timar J, Schäfer R. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.  Breast Cancer Res Treat 132: 1025-1034

Schäfer R and Sers C. RAS oncogene-mediated deregulation of the transcriptome: From molecular signature to function. Adv. Enzyme Reg. 51: 126-136.

EXPERTS

Dr. Alessandra Silvestri

head of cell culture lab

  MAIL TO

Alessandra Silvestri has studied Pharmaceutical Chemistry and Technology at University of Trieste, Italy. In 2007 she started her PhD at National Cancer Institute, CRO-Aviano, Italy in the group of Professor Colombatti and in collaboration with Dr Belluco, working in the field of translational medicine. The aim of her PhD project was to determine predictive and prognostic biomarkers to improve metastatic colorectal cancer patients management. During her PhD she spent 18 months in the group of Dr Liotta and Dr Petricoin at George Mason University, USA, where she specialized in phosphoproteomic profiling of tumor specimens using Reverse Phase Protein Microarray technology. After obtaining her PhD in 2010, she continued her activity at CRO-Aviano as a Post Doc improving the Laser Capture Microdissection facility and supporting the phosphoproteomic group of the Institute. In particular she focused on the analysis of tumor heterogeneity in colorectal cancer and how this can influence diagnostic approaches in clinical pathology. In 2012 she moved to University Tor Vergata, Rome in the group of Professor Cesareni where she focused on the understanding of the mechanism of action of Metformin as anti-cancer agent. In particular she studied the influence of tumor metabolism on metformin anti-cancer effect to determine how to enhance metformin efficacy with combination therapies aimed to alter tumor metabolism.

Manuela Gaebler, Alessandra Silvestri, Johannes Haybaeck, Peter Reichardt, Caitlin D. Lowery, Louis F. Stancato, Gabriele Zybarth and Christian R. A. Regenbrecht. Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management. Front Onc. 2017 Sep 11 

Zupa A, Improta G, Silvestri A, Pin E, Deng J, Aieta M, Musto P, Nitti D, Mammano E, Liotta L, Belluco C, Wulfkuhle J, Petricoin E 3rd. A pilotcharacterization of human lung NSCLC by protein pathway activation mapping. JThorac Oncol. 2012 Dec;7(12):1755-66. doi: 10.1097/JTO.0b013e3182725fc7. PubMedPMID: 23154546.

Silvestri A, Calvert V, Belluco C, Lipsky M, De Maria R, Deng J, Colombatti A, De Marchi F, Nitti D, Mammano E, Liotta L, Petricoin E, Pierobon M. Proteinpathway activation mapping of colorectal metastatic progression revealsmetastasis-specific network alterations. Clin Exp Metastasis. 2013Mar;30(3):309-16. doi: 10.1007/s10585-012-9538-5. Epub 2012 Sep 29. PubMed PMID: 23053743.

Gallagher RI, Silvestri A, Petricoin EF 3rd, Liotta LA, Espina V. Reverse phase protein microarrays: fluorometric and colorimetric detection. Methods MolBiol. 2011;723:275-301. doi: 10.1007/978-1-61779-043-0_18. PubMed PMID: 21370072.

Silvestri A, Colombatti A, Calvert VS, Deng J, Mammano E, Belluco C, De MarchiF, Nitti D, Liotta LA, Petricoin EF, Pierobon M. Protein pathway biomarkeranalysis of human cancer reveals requirement for upfront cellular-enrichmentprocessing. Lab Invest. 2010 May;90(5):787-96. doi: 10.1038/labinvest.2010.47.Epub 2010 Mar 1. PubMed PMID: 20195244.

Van Meter AJ, Rodriguez AS, Bowman ED, Jen J, Harris CC, Deng J, Calvert VS, Silvestri A, Fredolini C, Chandhoke V, Petricoin EF 3rd, Liotta LA, Espina V. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics. 2008 Oct;7(10):1902-24. doi: 10.1074/mcp.M800204-MCP200. Epub2008 Aug 6. PubMed PMID: 18687633; PubMed Central PMCID: PMC2559935.

Verdone G, Doliana R, Corazza A, Colebrooke SA, Spessotto P, Bot S, Bucciotti F, Capuano A, Silvestri A, Viglino P, Campbell ID, Colombatti A, Esposito G. The solution structure of EMILIN1 globular C1q domain reveals a disordered insertion necessary for interaction with the α4β1 integrin. J Biol Chem. 2008 Jul4;283(27):18947-56. doi: 10.1074/jbc.M801085200. Epub 2008 May 7. PubMed PMID:18463100.

Maxine Sil'vestrov, MSc

cell culture expert

  MAIL TO

Maxine Sil’vestrov finished her bachelor of science in the field of biotechnology specializing in cell biology at the Technical University of Braunschweig in 2009.  She also has a  Master degree for molecular life science from the Humboldt University of Berlin. The aim of her master thesis was the differentiation of mouse embryonic stem cell to hepatocytes which she accomplished in the department of experimental pharmacology in the group of Dr Iduna Fichtner at the Max Delbruck Center for Molecular Medicine in Berlin-Buch. Before she joined cpo in 2014 Maxi has worked at  EPO – experimental pharmacology & oncology Berlin-Buch GmbH.

Schütte M, [...], Silvestrov M, [...], Regenbrecht CRA et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun. 2017 Feb 10;8:14262. PubMed PMID: 28186126.

VISITING SCIENTISTS